Description
AstraZeneca: A Tale Of Oncology, Rare Diseases & Big Acquisitions!
AstraZeneca presented robust financial outcomes for the year 2024, achieving a total revenue growth of 21% and an increase in core earnings per share (EPS) of 19%. This reflects solid demand across its diverse portfolio and geographical footprint. The company’s strategic focus led to numerous pipeline advancements, notably nine high-value pivotal trial readouts that signify future growth potential, with an ambition to introduce 20 new medicines by 2030.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
